Hydroxyurea Active Not Recruiting Phase NA Trials for Sickle ... | 合法藥品大搜索

Hydroxyurea is an antimetabolite used to treat sickle cell anemia crisis. Brand Names. Droxia, Hydrea, Siklos. Generic Name: Hydroxyurea; DrugBank Accession ... Read More

clinicaltrials.gov Identifier, Title, Drugs. NCT01848925, Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients. Read More

clinicaltrials.gov Identifier, Title, Drugs. NCT02769845, SACRED A Prospective Research Study to Reduce Stroke in Children With Sickle Cell Anemia. Read More

clinicaltrials.gov Identifier, Title, Drugs. NCT00154375, Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral ... Read More

clinicaltrials.gov Identifier, Title, Drugs. NCT01521299, A Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid ... Read More

clinicaltrials.gov Identifier, Title, Drugs. NCT00056433, Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia. Read More

clinicaltrials.gov Identifier, Title, Drugs. NCT00402480, Hydroxyurea to Prevent Stroke in Children With Sickle Cell Anemia and Elevated TCD Flow Velocity. Read More

Hydroxyurea Terminated Phase 2 Trials for Hemoglobin SC Disease Treatment. Back to Hydroxyurea. Indications, Status, Purpose, Phase ... Read More

Hydroxyurea Completed Phase 4 Trials for Drepanocytic Men Treated by Hydroxyurea for the First Time Treatment. Back to Hydroxyurea ... Read More

Hydroxyurea | CH4N2O2 | CID 3657 - structure, chemical names, physical and chemical ... DrugBank. Hydroxyurea is readily absorbed from the GI tract. Read More